Your browser doesn't support javascript.
loading
Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives.
Buocikova, Verona; Rios-Mondragon, Ivan; Pilalis, Eleftherios; Chatziioannou, Aristotelis; Miklikova, Svetlana; Mego, Michal; Pajuste, Karlis; Rucins, Martins; Yamani, Naouale El; Longhin, Eleonora Marta; Sobolev, Arkadij; Freixanet, Muriel; Puntes, Victor; Plotniece, Aiva; Dusinska, Maria; Cimpan, Mihaela Roxana; Gabelova, Alena; Smolkova, Bozena.
Afiliación
  • Buocikova V; Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.
  • Rios-Mondragon I; Department of Clinical Dentistry, University of Bergen, Aarstadveien 19, 5009 Bergen, Norway.
  • Pilalis E; e-NIOS Applications Private Company, Alexandrou Pantou 25, 17671 Kallithea, Greece.
  • Chatziioannou A; Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.
  • Miklikova S; e-NIOS Applications Private Company, Alexandrou Pantou 25, 17671 Kallithea, Greece.
  • Mego M; Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.
  • Pajuste K; Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.
  • Rucins M; 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.
  • Yamani NE; Latvian Institute of Organic Synthesis, Aizkraukles str. 21, LV-1006 Riga, Latvia.
  • Longhin EM; Latvian Institute of Organic Synthesis, Aizkraukles str. 21, LV-1006 Riga, Latvia.
  • Sobolev A; Health Effects Laboratory, NILU-Norwegian Institute for Air Research, 2007 Kjeller, Norway.
  • Freixanet M; Health Effects Laboratory, NILU-Norwegian Institute for Air Research, 2007 Kjeller, Norway.
  • Puntes V; Latvian Institute of Organic Synthesis, Aizkraukles str. 21, LV-1006 Riga, Latvia.
  • Plotniece A; Vall d Hebron, Institut de Recerca (VHIR), 08035 Barcelona, Spain.
  • Dusinska M; Vall d Hebron, Institut de Recerca (VHIR), 08035 Barcelona, Spain.
  • Cimpan MR; Institut Català de Nanosciència i Nanotecnologia (ICN2), Bellaterra, 08193 Barcelona, Spain.
  • Gabelova A; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
  • Smolkova B; Latvian Institute of Organic Synthesis, Aizkraukles str. 21, LV-1006 Riga, Latvia.
Cancers (Basel) ; 12(12)2020 Dec 03.
Article en En | MEDLINE | ID: mdl-33287297
Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article